Presbyopia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Presbyopia Pipeline Drugs Market Report Overview

Presbyopia is an eye condition in which the eye slowly loses the ability to focus quickly on close objects. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print, and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis, and eye trauma.

The Presbyopia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Presbyopia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects.

Presbyopia Pipeline Drugs Market Segmentation by Targets

The key targets in the Presbyopia pipeline drugs market are Cholinergic Receptor Muscarinic, Alpha 2 Adrenergic Receptor, Alpha 1 Adrenergic Receptor, Alpha Crystallin A Chain, and others. Cholinergic Receptor Muscarinic has the highest number of products in development in the Presbyopia pipeline drugs market.

Presbyopia Pipeline Drugs Market Analysis by Targets

Presbyopia Pipeline Drugs Market Analysis by TargetsFor more target insights into the Presbyopia pipeline drugs market, download a free report sample

Presbyopia Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Presbyopia pipeline drugs market are Cholinergic Receptor Muscarinic Agonist, Alpha 2 Adrenergic Receptor Agonist, Alpha 1 Adrenergic Receptor Antagonist, Alpha 2 Adrenergic Receptor Antagonist, and others. Cholinergic Receptor Muscarinic Agonist leads the Presbyopia pipeline drugs market in terms of MoA.

Presbyopia Pipeline Drugs Market Analysis by Mechanisms of Action

Presbyopia Pipeline Drugs Market Analysis by Mechanisms of ActionFor more MoA insights into the Presbyopia pipeline drugs market, download a free report sample

Presbyopia Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Presbyopia pipeline drugs market are ophthalmic, topical, and intravenous. The ophthalmic RoA has the highest number of Presbyopia drugs in development in 2022.

Presbyopia Pipeline Drugs Market Analysis by Routes of Administration

Presbyopia Pipeline Drugs Market Analysis by Routes of AdministrationFor more RoA insights into the Presbyopia pipeline drugs market, download a free report sample

Presbyopia Pipeline Drugs Market Segmentation by Molecule Types

The key molecule type in the Presbyopia pipeline drugs market is small molecule.

Presbyopia Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Presbyopia pipeline drugs market are Lenz Therapeutics LLC, KSbitugen Co Ltd, Ocuphire Pharma Inc, and Santen Pharmaceutical Co Ltd. Lenz Therapeutics LLC accounted for the highest number of Presbyopia drugs in development in 2022.

Presbyopia Pipeline Drugs Market Analysis by Companies

Presbyopia Pipeline Drugs Market Analysis by CompaniesTo know more about the leading Presbyopia pipeline drugs market players, download a free report sample

Presbyopia Pipeline Products Market Overview

Key Targets Cholinergic Receptor Muscarinic, Alpha 2 Adrenergic Receptor, Alpha 1 Adrenergic Receptor, Alpha Crystallin A Chain, and Others
Key Mechanisms of Action Cholinergic Receptor Muscarinic Agonist, Alpha 2 Adrenergic Receptor Agonist, Alpha 1 Adrenergic Receptor Antagonist, Alpha 2 Adrenergic Receptor Antagonist, and Others
Key Routes of Administration Ophthalmic, Topical, and Intravenous
Key Molecule Type Small Molecule
Leading Companies Lenz Therapeutics LLC, KSbitugen Co Ltd, Ocuphire Pharma Inc, Santen Pharmaceutical Co Ltd, and Others

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia.
  • The pipeline guide reviews pipeline therapeutics for Presbyopia by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Presbyopia therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Presbyopia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Presbyopia

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Presbyopia.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the Presbyopia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

AbbVie Inc
Cellix Bio Pvt Ltd
Eyenovia Inc
Glaukos Corp
KSbitugen Co Ltd
Kubota Vision Inc
Lenz Therapeutics LLC
Novartis AG
Ocuphire Pharma Inc
Orasis Pharmaceuticals Ltd
Plex Pharmaceuticals Inc
Reven Holdings Inc
Santen Pharmaceutical Co Ltd
Seinda Pharmaceutical Guangzhou Corp
Theratocular Biotek Co Ltd
Visus Therapeutics Inc
Vyluma Inc
Zhejiang Raytone Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Presbyopia – Overview

Presbyopia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Presbyopia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Presbyopia – Companies Involved in Therapeutics Development

AbbVie Inc

Cellix Bio Pvt Ltd

Eyenovia Inc

Glaukos Corp

KSbitugen Co Ltd

Kubota Vision Inc

Lenz Therapeutics LLC

Novartis AG

Ocuphire Pharma Inc

Orasis Pharmaceuticals Ltd

Plex Pharmaceuticals Inc

Reven Holdings Inc

Santen Pharmaceutical Co Ltd

Seinda Pharmaceutical Guangzhou Corp

Theratocular Biotek Co Ltd

Visus Therapeutics Inc

Vyluma Inc

Zhejiang Raytone Biotechnology Co Ltd

Presbyopia – Drug Profiles

(aceclidine + brimonidine) – Drug Profile

Product Description

Mechanism Of Action

(aceclidine + tropicamide) – Drug Profile

Product Description

Mechanism Of Action

(brimonidine tartrate + carbachol) – Drug Profile

Product Description

Mechanism Of Action

(diclofenac sodium + pilocarpine hydrochloride) – Drug Profile

Product Description

Mechanism Of Action

(phentolamine mesylate + pilocarpine) – Drug Profile

Product Description

Mechanism Of Action

aceclidine – Drug Profile

Product Description

Mechanism Of Action

AGN-241622 – Drug Profile

Product Description

Mechanism Of Action

CAP-1160 – Drug Profile

Product Description

Mechanism Of Action

CLXOPH-561 – Drug Profile

Product Description

Mechanism Of Action

GLK-302 – Drug Profile

Product Description

Mechanism Of Action

Kinase Derivatives – Drug Profile

Product Description

Mechanism Of Action

KSB-10201 – Drug Profile

Product Description

Mechanism Of Action

KT-101 – Drug Profile

Product Description

Mechanism Of Action

NVK-029 – Drug Profile

Product Description

Mechanism Of Action

phentolamine mesylate – Drug Profile

Product Description

Mechanism Of Action

pilocarpine – Drug Profile

Product Description

Mechanism Of Action

RPEC-1004A – Drug Profile

Product Description

Mechanism Of Action

RTP-003A – Drug Profile

Product Description

Mechanism Of Action

RTP-003B – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Presbyopia and Cataract – Drug Profile

Product Description

Mechanism Of Action

Small-Molecule Therapeutics – Drug Profile

Product Description

Mechanism Of Action

SY-301 – Drug Profile

Product Description

Mechanism Of Action

TOO-1005 – Drug Profile

Product Description

Mechanism Of Action

ursodiol – Drug Profile

Product Description

Mechanism Of Action

VP-1001 – Drug Profile

Product Description

Mechanism Of Action

Presbyopia – Dormant Projects

Presbyopia – Product Development Milestones

Featured News & Press Releases

Nov 02, 2022: Ocuphire announces peer-reviewed publication in BMC Ophthalmology for Nyxol and strategic partnership with American Society of Ophthalmic Administrators (ASOA)

Oct 28, 2022: Ocuphire announces poster presentations on Nyxol at the American Academy of Optometry Annual Meeting

Oct 20, 2022: Eyenovia announces positive results from VISION-2 phase 3 study of MicroLine as a potential on-demand treatment for presbyopia

Oct 03, 2022: Ocuphire announces upcoming presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting

Jul 06, 2022: Eyenovia strategic partner Arctic Vision enrolls first patient in phase III clinical trial of ARVN003 (MicroLine) for Presbyopia in China

Jul 05, 2022: Arctic Vision enrols first subject in Phase III presbyopia trial

Apr 27, 2022: Visus Therapeutics announces new scientific data to be presented during the 2022 ARVO Annual Meeting

Apr 26, 2022: Ocuphire announces upcoming clinical presentation on Nyxol at ARVO 2022 Medical Meeting and MODLive! 2022

Apr 23, 2022: Orasis Pharmaceuticals announces phase 2b trial efficacy and safety results of novel presbyopia eye drop candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 21, 2022: Orasis Pharmaceuticals announces positive phase 3 topline results of Novel Eye Drop Candidate, CSF-1, for the treatment of presbyopia

Apr 12, 2022: Orasis Pharmaceuticals to present new data on novel presbyopia candidate at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Mar 22, 2022: Visus Therapeutics initiates phase 3 pivotal trials of BRIMOCHOL PF for the treatment of presbyopia

Mar 15, 2022: Orasis Pharmaceuticals concludes phase 3 clinical trials for presbyopia candidate

Feb 08, 2022: Ocuphire completes enrollment in MIRA-3 Pivotal phase 3 clinical trial for Nyxol in RM and announces upcoming medical conference presentation

Jan 11, 2022: Glaukos announces first patient enrolled in phase 2 clinical trial for presbyopia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Presbyopia, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Presbyopia – Pipeline by AbbVie Inc, 2022

Presbyopia – Pipeline by Cellix Bio Pvt Ltd, 2022

Presbyopia – Pipeline by Eyenovia Inc, 2022

Presbyopia – Pipeline by Glaukos Corp, 2022

Presbyopia – Pipeline by KSbitugen Co Ltd, 2022

Presbyopia – Pipeline by Kubota Vision Inc, 2022

Presbyopia – Pipeline by Lenz Therapeutics LLC, 2022

Presbyopia – Pipeline by Novartis AG, 2022

Presbyopia – Pipeline by Ocuphire Pharma Inc, 2022

Presbyopia – Pipeline by Orasis Pharmaceuticals Ltd, 2022

Presbyopia – Pipeline by Plex Pharmaceuticals Inc, 2022

Presbyopia – Pipeline by Reven Holdings Inc, 2022

Presbyopia – Pipeline by Santen Pharmaceutical Co Ltd, 2022

Presbyopia – Pipeline by Seinda Pharmaceutical Guangzhou Corp, 2022

Presbyopia – Pipeline by Theratocular Biotek Co Ltd, 2022

Presbyopia – Pipeline by Visus Therapeutics Inc, 2022

Presbyopia – Pipeline by Vyluma Inc, 2022

Presbyopia – Pipeline by Zhejiang Raytone Biotechnology Co Ltd, 2022

Presbyopia – Dormant Projects, 2022

Figures

List of Figures

Number of Products under Development for Presbyopia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Presbyopia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Presbyopia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Presbyopia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Presbyopia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.